Literature DB >> 31694894

Brain Metastases from Biliary Tract Cancers: A Case Series and Review of the Literature in the Genomic Era.

Megan R D'Andrea1, Corey M Gill1, Melissa Umphlett2, Nadejda M Tsankova2, Mary Fowkes2, Joshua B Bederson1, Priscilla K Brastianos3, Raj K Shrivastava1.   

Abstract

BACKGROUND: Biliary tract cancers (BTCs) are highly fatal malignancies that make up less than 1% of all cancers. BTC is often diagnosed at an unresectable stage; surgical resection remains the only definitive treatment. Brain metastases (BMs) from BTC are extremely rare, and few studies on patients with BMs from BTC exist. The aim of this study was to identify clinical characteristics associated with poor prognosis for patients with BMs from BTC.
MATERIALS AND METHODS: We performed a retrospective review of electronic medical records for patients with BMs from BTC managed at Mount Sinai Hospital from 2000 to 2017. Data on patient characteristics, magnetic resonance imaging findings, treatment regimens, and clinical outcomes were analyzed.
RESULTS: We identified 1,910 patients with BTC. Nine patients developed BMs, with an incidence of 0.47%. Of these nine patients, six had intrahepatic cholangiocarcinoma, two had extrahepatic cholangiocarcinoma, and one had gallbladder cancer. Six (66.7%) patients had one BM, one (11.1%) patient had two BMs, and two (22.2%) patients had three or more BMs. Four (44.4%) patients underwent BM resection, and seven (77.8%) received BM radiation. Median overall survival from time of BM diagnosis was 3.8 months (95% confidence interval 0.1-16.9).
CONCLUSION: Development of BMs from BTC is rare; however, prognosis is less than 4 months. BM diagnosis can occur within 2 years of primary diagnosis. As targeted therapeutics emerge, future studies ought to focus on identifying genomic BM markers associated with BTC subtypes. IMPLICATIONS FOR PRACTICE: In the largest retrospective study of biliary tract cancer brain metastases, the clinical presentation and outcomes are reported of nine patients with an extremely rare clinical entity. The genomic literature and potential therapeutic targets for these patients with limited treatment options is comprehensively and exhaustively discussed. © AlphaMed Press 2019.

Entities:  

Keywords:  Biliary tract cancer; Brain metastases; Cholangiocarcinoma; Gallbladder cancer; Genomics

Mesh：

Year:  2019        PMID： 31694894      PMCID： PMC7216433          DOI： 10.1634/theoncologist.2019-0306

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


  54 in total

1.  Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers.

Authors:  Tanios Bekaii-Saab; Mitch A Phelps; Xiaobai Li; Motoyasu Saji; Laura Goff; John Sae Wook Kauh; Bert H O'Neil; Stephanie Balsom; Catherine Balint; Ryan Liersemann; Vasily V Vasko; Mark Bloomston; William Marsh; L Austin Doyle; Gilian Ellison; Michael Grever; Matthew D Ringel; Miguel A Villalona-Calero
Journal:  J Clin Oncol       Date:  2011-04-25       Impact factor: 44.544

2.  Phase I trial of dovitinib (TKI258) in recurrent glioblastoma.

Authors:  Niklas Schäfer; Gerrit H Gielen; Sied Kebir; Anja Wieland; Andreas Till; Frederic Mack; Christina Schaub; Theophilos Tzaridis; Roman Reinartz; Michael Niessen; Rolf Fimmers; Matthias Simon; Christoph Coch; Christine Fuhrmann; Ulrich Herrlinger; Björn Scheffler; Martin Glas
Journal:  J Cancer Res Clin Oncol       Date:  2016-04-21       Impact factor: 4.553

3.  Cholangiocarcinoma and brain lesions: an extremely rare finding.

Authors:  Aibek E Mirrakhimov; Nwabundo Nwankwo; Teresita Zdunek; Nora Bucher
Journal:  BMJ Case Rep       Date:  2013-05-09

4.  HER2/neu may not be an interesting target in biliary cancers: results of an early phase II study with lapatinib.

Authors:  Joshua Peck; Lai Wei; Mark Zalupski; Bert O'Neil; Miguel Villalona Calero; Tanios Bekaii-Saab
Journal:  Oncology       Date:  2012-03-15       Impact factor: 2.935

5.  SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma.

Authors:  Anthony B El-Khoueiry; Cathryn J Rankin; Edgar Ben-Josef; Heinz-Josef Lenz; Philip J Gold; R Darryl Hamilton; Rangaswamy Govindarajan; Cathy Eng; Charles D Blanke
Journal:  Invest New Drugs       Date:  2011-07-12       Impact factor: 3.850

6.  Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer.

Authors:  Eric Tran; Simon Turcotte; Alena Gros; Paul F Robbins; Yong-Chen Lu; Mark E Dudley; John R Wunderlich; Robert P Somerville; Katherine Hogan; Christian S Hinrichs; Maria R Parkhurst; James C Yang; Steven A Rosenberg
Journal:  Science       Date:  2014-05-09       Impact factor: 47.728

7.  Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation.

Authors:  Eunice L Kwak; Geoffrey I Shapiro; Seth M Cohen; Carlos R Becerra; Heinz-Josef Lenz; Wen-Fang Cheng; Wu-Chou Su; Meghan Robohn; Florence Le Maulf; Maximilian T Lobmeyer; Vikram K Chand; A John Iafrate
Journal:  Cancer       Date:  2013-06-14       Impact factor: 6.860

8.  Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study.

Authors:  David K Lau; Rebecca Y Tay; Yvonne H Yeung; Fiona Chionh; Jennifer Mooi; Carmel Murone; Effie Skrinos; Timothy J Price; John M Mariadason; Niall C Tebbutt
Journal:  Br J Cancer       Date:  2018-03-12       Impact factor: 7.640

9.  Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma.

Authors:  Mitesh J Borad; Mia D Champion; Jan B Egan; Winnie S Liang; Rafael Fonseca; Alan H Bryce; Ann E McCullough; Michael T Barrett; Katherine Hunt; Maitray D Patel; Scott W Young; Joseph M Collins; Alvin C Silva; Rachel M Condjella; Matthew Block; Robert R McWilliams; Konstantinos N Lazaridis; Eric W Klee; Keith C Bible; Pamela Harris; Gavin R Oliver; Jaysheel D Bhavsar; Asha A Nair; Sumit Middha; Yan Asmann; Jean-Pierre Kocher; Kimberly Schahl; Benjamin R Kipp; Emily G Barr Fritcher; Angela Baker; Jessica Aldrich; Ahmet Kurdoglu; Tyler Izatt; Alexis Christoforides; Irene Cherni; Sara Nasser; Rebecca Reiman; Lori Phillips; Jackie McDonald; Jonathan Adkins; Stephen D Mastrian; Pamela Placek; Aprill T Watanabe; Janine Lobello; Haiyong Han; Daniel Von Hoff; David W Craig; A Keith Stewart; John D Carpten
Journal:  PLoS Genet       Date:  2014-02-13       Impact factor: 5.917

10.  Identification of targetable FGFR gene fusions in diverse cancers.

Authors:  Yi-Mi Wu; Fengyun Su; Shanker Kalyana-Sundaram; Nickolay Khazanov; Bushra Ateeq; Xuhong Cao; Robert J Lonigro; Pankaj Vats; Rui Wang; Su-Fang Lin; Ann-Joy Cheng; Lakshmi P Kunju; Javed Siddiqui; Scott A Tomlins; Peter Wyngaard; Seth Sadis; Sameek Roychowdhury; Maha H Hussain; Felix Y Feng; Mark M Zalupski; Moshe Talpaz; Kenneth J Pienta; Daniel R Rhodes; Dan R Robinson; Arul M Chinnaiyan
Journal:  Cancer Discov       Date:  2013-04-04       Impact factor: 39.397
View more
  1 in total

1.  Sixth Cranial Nerve Palsy as the Presenting Sign of Metastatic Cholangiocarcinoma.

Authors:  Benjamin J Fowler; Byron L Lam
Journal:  Int Med Case Rep J       Date:  2020-11-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.